News Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
News Roswell Park Presents ‘Highly Encouraging’ Phase 2A Results on SurVaxM Immunotherapy for Glioblastoma
News Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM